Actively Recruiting

All Genders
NCT04172025

Development of a Swiss Surveillance Database for Molecular Epidemiology of Hypervirulent and Multi-drug Resistant Pathogens

Led by University Hospital, Basel, Switzerland · Updated on 2025-05-14

10000

Participants Needed

5

Research Sites

535 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Basel, Switzerland

Lead Sponsor

S

Swiss National Science Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Hypervirulent and multidrug-resistant infections are associated with significant health care costs, substantial morbidity and mortality. Therefore, the rapid recognition of outbreaks and transmissions with hypervirulent and multi-drug resistant pathogen is a key priority for infection control and public health.The main goal is to implement a shared database, connecting human and veterinary microbiology laboratories, which would allow near real-time molecular epidemiology with high spatiotemporal resolution of bacterial pathogens such as transmission and outbreak surveillance between different compartments including humans, animals and the environment in Switzerland. Investigator aims to analyze already collected encoded retrospective datasets of various pathogens by combining epidemiological data and whole genome sequences from pathogens.

CONDITIONS

Official Title

Development of a Swiss Surveillance Database for Molecular Epidemiology of Hypervirulent and Multi-drug Resistant Pathogens

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with colonization or infection by bacterial or viral pathogens with available whole genome sequencing data
  • Availability of minimal epidemiological, demographic, and clinical data for the patient
  • Pathogens included: multidrug-resistant bacteria (e.g., MRSA, ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, Vancomycin resistant Enterococcus faecium), virulent bacteria (e.g., Neisseria meningitidis, Neisseria gonorrhoeae, Mycobacterium tuberculosis, Campylobacter, Salmonella, Legionella pneumophila, Listeria monocytogenes, Streptococcus pneumoniae), and viruses (e.g., Influenza viruses, Measles virus, Enterovirus E68, Respiratory Syncytial Virus)
Not Eligible

You will not qualify if you...

  • Decline to sign general consent or any other statement refusing use of data for research purposes

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

University Hospital Basel

Basel, Switzerland, 4031

Actively Recruiting

2

University of Bern

Bern, Switzerland, 3012

Actively Recruiting

3

University Hospital Geneva

Geneva, Switzerland, 1205

Actively Recruiting

4

University Hospital Lausanne CHUV

Lausanne, Switzerland, 1011

Actively Recruiting

5

University of Zurich

Zurich, Switzerland, 8057

Actively Recruiting

Loading map...

Research Team

H

Hans Hirsch, Prof. Dr.

CONTACT

A

Aitana Lebrand, Dr.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here